Oxford to study anti-inflammatory drug Hamira as potential COVID-19 treatment

By Josephine Mason and Kate Kelland

LONDON (Reuters) – Oxford University said on Wednesday that it would study whether the world’s best-selling prescription medicine, adultifab, was an effective treatment for COVID-19 patients – potentially reproducing existing drugs as coronav therapy Latest effort.

Adalimumab, which is sold by AbbVie under the brand name Humira, is a type of anti-inflammatory known as an anti-tumor necrosis factor (anti-TNF) drug. Recent studies have shown that COVID-19 patients are already taking anti-TNF drugs for inflammatory bowel disease and are less likely to be hospitalized for inflammatory arthritis, Oxford said in a statement.

According to the university, the aim of Oxford-CC, called AVD-CC, would be to treat people in the community. It will recruit 750 patients from community care settings across the UK.

Hamira is used for the treatment of many conditions including rheumatism, Crohn’s disease, ulcerative colitis, and psoriasis.

Oxford said that if a biosimilar version of the drug is available, it will become cheaper and accessible. Novartis makes a choice, Harimoz.

Research has identified some treatments for hospitalized COVID-19 patients, including Gilead’s Remedisvir, as well as the generic steroid drug dexamethasone.

Researchers have also studied other anti-inflammatory drugs for the treatment of COVID-19. Severe infections are believed to be triggered by an over-reaction of the immune system, known as cytokine storms, and drugs that suppress certain elements of the immune system, arresting the rapid increase of symptoms Can play a role.

But there are no effective treatments yet for people who are not hospitalized.

Care homes were particularly difficult in the UK and other countries since the first wave of COVID-19. If Hamira is successful against COVID-19, it could help some older people who are some of the most vulnerable, he said, at a time when governments are struggling to stop the epidemic.

The Oxford study is funded by the global health charity Welcome, as well as the COVID-19 medical science accelerator initiative established by the Bill & Melinda Gates Foundation and MasterCard.

(Reporting by Josephine Mason and Kate Kelland in London and John Miller in Zurich; Editing by Mark Heinen)

Leave a Reply

Your email address will not be published.